Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, C4 Therapeutics, Inc. reported revenue of $36M, up 1.0% year over year. Operating margin was -320.5% and net margin -292.1%, on a free-cash-flow margin of -276.2% with capital expenditure at 1.7% of revenue. Every figure is computed directly from CCCC's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $36M | -320.5% | -292.1% |
| FY2024 | $36M | -336.1% | -296.0% |
| FY2023 | $21M | -669.8% | -638.3% |
| FY2022 | $31M | -416.6% | -412.2% |
| FY2021 | $46M | -179.4% | -183.2% |
How does CCCC compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.